Attorney's Docket No. 016914-039

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Thorsteinn LOFTSSON et al.

Group Art Unit: 1623

Application No.: 10/750,940

Examiner:

Filed: January 5, 2004

Confirmation No.: 2037

For:

HIGH-ENERGY CYCLODEXTRIN

COMPLEXES

## FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants are submitting herewith a Form PTO-1449 substitute (two sheets) listing documents for consideration by the Examiner.

All of the listed documents were previously made of record in prior Application Serial No. 09/250,185, filed February 16, 1999, upon which Applicants rely for the benefits provided in 35 U.S.C. § 120. In accordance with 37 C.F.R. § 1.98, further copies of these documents are not required to be filed herein.

This statement and accompanying Form PTO-1449 substitute are being submitted together with the Missing Parts and thus before the first Office Action on the merits. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

It is respectfully requested that this Information Disclosure Statement be acknowledged and that a copy of applicants Form PTO-1449 substitute (2 sheets) be returned to the undersigned with the next official communication.

> Respectfully submitted, BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date May 21, 2004

Mary Katherine Bauméister Registration No. 26,254

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

## Substitute for form 1449A/PTO & 1449B/PTO **FIRST**

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

Complete if Known					
Application Number	10/750,940				
Filing Date	January 5, 2004				
First Named Inventor	Thorsteinn LOFTSSON et al.				
Examiner Name					
Attorney Docket Number	016914-039				

(use as many sheets as necessary) of

PAR Z I ZU			U.S. PATENT DOCUMENTS	
Examiner of the party of the pa	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	5,134,127	Α	Stella et al.	07-28-1992
	5,324,718		Loftsson	06-28-1994
	5,376,645		Stella et al.	12-27-1994
	5,472,954		Loftsson	12-05-1995

			FOREIGN PATENT DOCUME	ENTS		
Examiner	Document	Kind Code	Country	Date of Publication	Translation	
Initials	Number	(if known)	•	(MM-DD-YYYY)	Yes	No
	94/02518		WO	02-03-1994		•

	NON-PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Oh et al, International Journal of Pharmaceutics, 73, pp. 23-31 (1991).
	Loftsson and Brewster, Pharm. Technol. Eur., 9(5), 26-34 (May 1997).
	Loftsson and Brewster, J. Pharm. Sci., 85(10), 1017-1025 (October 1996).
	Rajewski and Stella, <i>J. Pharm. Sci.</i> , 85 (11), 1142-1169 (November 1996).
<u>-</u>	Irie and Uekama, J. Pharm. Sci., 86(2), 147-162 (February 1997).
	Stella and Rajewski, <i>Pharm. Res.</i> , 14(5), 556-567 (1997).
	Loftsson, <i>Pharmazie</i> , 53, 733-740 (1998).
	Frömming and Szejtli, Cyclodextrins in Pharmacy, Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 105-107 (1994).
	Loftsson and Ólafsson, Int. J. Dermatol., 37, 241-246 (1998).
	Loftsson and Stefánsson, Drug. Dev. Ind. Pharm., 23 (5), 473-481 (1997).
	Loftsson, Másson and Stefánsson, "Cyclodextrins as Permeation Enhancers", <i>Proceedings of the 17<sup>th</sup> Pharmaceutical Technology Conference and Exhibition</i> , volume 2, Dublin, pp. 313-324 (24-26 March 1998).
	Schwartz, Rhodes and Cooper, J. Pharm. Sci., 66, 994-997 (July 1977).
	Loftsson and Bodor, Acta Pharm. Nord., 1, 185-194 (1989). (Issue No. 4).
	Loftsson and Sigudardóttir, "Cyclodextrins as skin penetration enhancers,", in J. Szejtli and Szente (eds)., <i>Proceedings of the Eighth International Symposium on Cyclodextrins</i> , Kluwer Academic Publishers, pp. 403-406 (1996).

Examiner Date \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO				Con	plete if Known
	F	IRST		Application Number	10/750,940
INFORMATION DISCLOSURE				Filing Date	January 5, 2004
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Thorsteinn LOFTSSON et al.
-	(use as man	sheets as	necessary)	Examiner Name	
Sheet	2	of	2	Attorney Docket Number	016914-039

-	NON-PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Roth, Eger and Troschütz, <i>Pharmaceutical Chemistry</i> , Volume 2: Drug Analysis, Ellis Horwood, pp. 308-309 (1991).
	Gerecke, Br. J. Clin. Pharmac., 11S-16S (1983).
. =	Pharmaceutical Chemistry, Volume 2: Drug Analysis, ed. H.J. Roth et al., pp. 302-311; 496-513; 518-525; 546-547; 580-581; 590-591; 594-597; 659-673; published by Ellis Horwood, London (1988).
	Chemical Stability of Pharmaceuticals, A Handbook for Pharmacists, Second Edition, ed. Kenneth A. Connors et al, pp. 257-263; 675 684; 764-773; published by Wiley-Interscience; John Wiley & Sons, New York (1986).
	Stenlake, Foundations of Molecular Pharmacology, Volume 1, Medicinal and Pharmaceutical Chemistry, pp. 512-513, published by The Athlone Press, University of London (1979).
	Junquera et al, <i>J. Org. Chem.</i> , 63, pp. 4349-4358 (1998). (WWW publ.: 06/11/98).
· · · <del></del>	Li et al, Journal of Pharmaceutical Sciences, 87, No. 12, pp. 1535-1537 (December 1998).
	Krishnamoorthy et al., "Complexation of Weak Acids and Bases with Cyclodextrins: Effects of Substrate Ionization and the Estimatio and Interpretation of Association Constants," <i>International J. of Pharmaceutical Advances, 1</i> (3), 330-343 (Jan., 1996).
	Loftsson et al., "Effects of 2-Hydroxypropyl-β-cyclodextrin on the Aqueous Solubility of Drugs and Transdermal Delivery of 17-β-Estradiol," <i>Acta Pharm. Nord. 1</i> (4), 185-194 (1989).
	Menard et al., "Studies on the Effect of pH, Temperature and ring Size on the Complexation of Phenytoin with Cyclodextrins," <i>Pharm Acta Helv.</i> , 63 (11), 303-308 (1988).
	Loftsson et al., "The Influence of Water-Soluble Polymers and pH on Hydroxylpropyl-β-cyclodextrin Complexation of Drugs," <i>Drug Development and Industrial Pharmacy</i> , 22 (5), 404-405 (1996); see also HCAPlus abstract.
	Selva et al., "Study of the Salts of Organic Hydroxy Acids of the Terfenadine β-Cyclodextrin Complex in Solution of Mass Spectrometry," <i>Journal of Mass Spectrometry</i> , 30 (1), 219-220 (1995).
	Fenyvesi et al., "Enhancement of the Drug Solubilizing Capacity of Hydroxypropyl-β-cyclodextrin by Ternary Complex Formation," in The 7 <sup>th</sup> Cyclodextrin Symposium, T. Osa (ed.), Business Center for Academic Societies Japan, Tokyo, Japan, 1994, pages 414-418.
	Vikmon et al., "Terfenadine/Cyclodextrin/Hydroxyacid Multicomponent Complexes," in The 7 <sup>th</sup> Cyclodextrin Symposium, T. Osa (ed.) Business Center for Academic Societies Japan, Tokyo, Japan, 1994, pages 480-483.
make .	,

Examiner	Date	
Signature	Considered	